Source: Healio News
The FDA granted fast track designation to EZM0414 for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
EZM0414 (Epizyme) is an oral SETD2 inhibitor. SETD2 is a histone methyltransferase that plays several important roles in oncogenesis, according to an Epizyme-issued press release.
The company has launched a phase 1/1b study to assess the safety of the agent and determine the optimal dose. After the dose-ranging phase, the study will be expanded to include three cohorts: patients with multiple myeloma and translocation t(4;14), multiple myeloma without